Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Splitting Ironwood

Why splitting in two could finally give Ironwood and investors their just rewards

May 5, 2018 12:12 AM UTC

Ironwood Pharmaceuticals Inc. has accomplished what many biotechs aspire to but few achieve. It has built a high-growth GI business on the cusp of profitability, and discovered and developed a well-stocked pipeline of clinical candidates to treat a range of serious, underserved diseases.

But unlike other biotechs that have reached this inflection point, its stock hasn’t been well-rewarded for either its commercial success or its R&D. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article